Merck shares Phase 3 trial results for its HIV-1 regimen, doravirine/islatravir, showing safety and comparable efficacy to ...

[1] Tenofovir disoproxil fumarate (Viread ... treated with a once-daily triple NRTI regimen containing didanosine, lamivudine, and tenofovir. The company reported the emergence of NRTI-resistance ...

Failure of a regime containing emtricitabine is likely to lead to the emergence of the M184V mutation, causing high-level resistance to lamivudine and low-level resistance to abacavir. See Tenofovir ...

HIV pre-exposure prophylaxis (PrEP) with daily oral tenofovir disoproxil fumarate (TDF) or TDF–emtricitabine (FTC) has been shown to be effective against sexual and injection-drug related HIV ...

Original Medicare, Medicare Advantage, and prescription drug (Part D) plans must cover generic emtricitabine/tenofovir disoproxil fumarate or brand name Truvada. Truvada is the brand name of a ...

The investigational therapy combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a nucleoside reverse transcriptase translocation inhibitor.

Merck, known as MSD outside the United States and Canada announced that the Food and Drug Administration (FDA) has approved two new HIV-1 medicines: Delstrigo and Pifeltro. The FDA has approved ...

The studies compared the two drug regimen with dolutegravir and a standard “backbone” of two nucleoside reverse transcriptase inhibitors – tenofovir disoproxil fumarate and emtricitabine ...

You should not take emtricitabine/tenofovir disoproxil fumarate with any of the following drugs: tenofovir alafenamide lamivudine adefovir dipivoxil. Taking emtricitabine/tenofovir disoproxil fumarate ...